Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

Our laboratory carried out research in two areas. In one, we studied the structure and mechanism of activity of the catalytic RNA moiety of the RNA processing enzyme ribo-nuclease P (Rnase P). In the ...

The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.

After hours: March 18 at 7:44:21 PM EDT Loading Chart for SANA ...

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investorsFinancing extends Arbor’s cash ...

Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I ...

Stoke Therapeutics, Inc. is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen ...

为探究宫颈癌（CC）放疗抵抗机制，研究人员聚焦凋亡肿瘤细胞来源的细胞外囊泡（apoEVs），发现 apoEV - MTA1 通过 p - STAT1/NR2F1 轴诱导细胞休眠，促进放疗抵抗，为 CC 治疗提供新策略。

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...